Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

SymBio gets rigosertib rights from Onconova

Executive Summary

Onconova Therapeutics Inc. (small-molecule cancer treatments) has granted SymBio Pharmaceuticals Ltd. (therapies for cancer, blood disorders, and autoimmune diseases) exclusive rights to develop and sell the oncology candidate ribosertib (which SymBio will code SyB1101) in Japan and Korea.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register